16.58  -0.26 (-1.54%)		05-22 16:00
Open: 16.85 High: 17.015 Volume: 21,921		Pre. Close: 16.84 Low: 16.58 Market Cap: 180(M)

Short term
Mid term
Targets	6-month :	19.92	1-year :	20.66
Resists	First :	17.05	Second :	17.69
Pivot price	16.75
Supports	First :	16.03	Second :	13.33
MAs	MA(5) :	16.67	MA(20) :	16.69
	MA(100) :	17.23	MA(250) :	18.11
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	48.4	D(3) :	46.7
RSI	RSI(14): 47.4
52-week	High :	22.5	Low :	14.89

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MDWD ] has closed above bottom band by 39.1%. Bollinger Bands are 18.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	17.02 - 17.14	17.14 - 17.23
Low:	16.36 - 16.47	16.47 - 16.56
Close:	16.42 - 16.6	16.6 - 16.75

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Thu, 21 May 2026
MDWD PE Ratio & Valuation, Is MDWD Overvalued - Intellectia AI

Fri, 15 May 2026
[SCHEDULE 13G] MediWound Ltd. Passive Investment Disclosure (>5%) - Stock Titan

Fri, 15 May 2026
MediWound Ltd. (MDWD) Presents at European Wound Management Association (EWMA) 2026 - Slideshow - Seeking Alpha

Thu, 07 May 2026
MediWound to Report First Quarter 2026 Financial Results - GlobeNewswire

Wed, 06 May 2026
Strong MediWound (MDWD) support for board and proposals at 2026 meeting - Stock Titan

Mon, 13 Apr 2026
MediWound highlights consensus supporting debridement strategy - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	13 (M)
Shares Float	10 (M)
Held by Insiders	15.8 (%)
Held by Institutions	58.2 (%)
Shares Short	1,530 (K)
Shares Short P.Month	1,560 (K)

EPS	-2.1
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.4
Profit Margin	-140.9 %
Operating Margin	-417.8 %
Return on Assets (ttm)	-19.8 %
Return on Equity (ttm)	-63.9 %
Qtrly Rev. Growth	-68 %
Gross Profit (p.s.)	0.25
Sales Per Share	1.31
EBITDA (p.s.)	-1.89
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-16 (M)

PE Ratio	-7.9
PEG Ratio	0
Price to Book value	4.87
Price to Sales	12.56
Price to Cash Flow	-13.22

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.